公开(公告)号：US20230211022A1

公开(公告)日：2023-07-06

申请号：US17810956

申请日：2022-07-06

Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  Modulation Therapeutics, Inc. ,  Wake Forest University Health Sciences

Inventor： David MORSE ,  Robert GILLIES ,  Mark MCLAUGHLIN ,  Thaddeus WADAS ,  Hyun Joo KIL ,  Narges TAFRESHI

IPC: A61K51/08 ,  G01N33/574 ,  C07K14/705 ,  A61K38/08 ,  A61P35/04 ,  C07K7/06 ,  A61K38/00

CPC classification number: A61K51/088 ,  G01N33/5743 ,  C07K14/705 ,  A61K38/08 ,  A61P35/04 ,  C07K7/06 ,  A61K38/00

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.

公开(公告)号：US11654181B2

公开(公告)日：2023-05-23

申请号：US16637498

申请日：2018-08-10

Applicant: Wake Forest University Health Sciences

Inventor： James K. Williams

IPC: A61K38/19 ,  A61P15/10 ,  A61K9/00 ,  A61K48/00

CPC classification number: A61K38/195 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0034 ,  A61P15/10 ,  A61K48/00

Abstract: This invention relates to C-X-C motif chemokine 12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1), vectors encoding the same, and methods of using the same for a male subject that has undergone prostate surgery to treat urological symptoms of the surgery.

公开(公告)号：US11622981B2

公开(公告)日：2023-04-11

申请号：US16947866

申请日：2020-08-21

Applicant: Wake Forest University Health Sciences

Inventor： Hariom Yadav ,  Shaohua Wang ,  Ravinder Nagpal

IPC: A61K35/747 ,  A61K9/00 ,  A61K9/19 ,  A61P1/00 ,  A61P29/00 ,  A23L33/135 ,  A23L33/00 ,  A61K31/7032 ,  A61K35/00

Abstract: Provided is a composition comprising an isolated Lactobacillus paracasei D3.5 strain or cellular components thereof. In some embodiments, the composition is provided in a pharmaceutically acceptable carrier, which may be a food product, tablet or capsule suitable for enteral administration, etc. Also provided is a composition comprising lipoteichoic acid isolated from Lactobacillus paracasei D3.5 strain, which may be provided in a pharmaceutically acceptable carrier.

公开(公告)号：US20220287749A1

公开(公告)日：2022-09-15

申请号：US17636454

申请日：2020-08-27

Applicant: Wake Forest University Health Sciences

Inventor： Philip Jayson Brown ,  Brandon Lee Roller

IPC: A61B17/84 ,  A61B17/88

Abstract: Systems for treating and/or preventing fractures include at least one needle sized and configured to be placed into target bone and at least one implantable pin configured to be releasably held in a first needle of the at least one needle. The systems also include at least one delivery device of injectable material configured to couple to the first needle while the first implantable pin is held in the first needle whereby the at least one delivery device and a respective needle cooperate to serially provide an external column of the injectable material about the at least one implantable pin.

公开(公告)号：US20220151994A1

公开(公告)日：2022-05-19

申请号：US17440229

申请日：2020-03-19

Applicant: Rafael Pharmaceuticals, Inc. ,  Memorial Sloan Kettering Cancer Center ,  Wake Forest University Health Sciences

Inventor： Timothy S. Pardee ,  Jeffrey Edelson ,  Ariela Noy ,  Zanetta Lamar

IPC: A61K31/4184 ,  A61K31/20 ,  A61K9/00 ,  A61P35/00

Abstract: The invention provides methods, compositions, and medical kits for treating lymphoma using 6,8-bis-benzylthio-octanoic acid or a pharmaceutically acceptable salt thereof, optionally in combination with a second therapeutic agent.

公开(公告)号：US11318106B2

公开(公告)日：2022-05-03

申请号：US16690558

申请日：2019-11-21

Applicant: Wake Forest University Health Sciences

Inventor： Benjamin S. Harrison ,  James J. Yoo ,  Anthony Atala

IPC: A61L15/26 ,  A61K9/70 ,  A61K31/77 ,  A61L15/18 ,  A61L15/64 ,  A61L26/00 ,  A61L27/44 ,  A61L27/58 ,  A61K38/00

Abstract: A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.

公开(公告)号：US11286231B2

公开(公告)日：2022-03-29

申请号：US16344452

申请日：2017-10-26

Applicant: Wake Forest University Health Sciences ,  Wake Forest University

Inventor： Mark E. Welker ,  Aleksander Skardal ,  Amber N. Weissenfluh ,  Surya Banks

IPC: C07C215/50 ,  C07C211/27 ,  C07C235/46 ,  C07C251/24 ,  C08B37/08 ,  C08L89/06 ,  A61L15/28 ,  A61L15/42 ,  A61L27/22 ,  A61L27/24 ,  A61L27/52

Abstract: Described herein are compounds having a hydrogen-bonding group and optionally a functional group for binding (e.g., covalently binding) the compound to another compound (e.g., hyaluronic acid and/or gelatin). A compound of the present invention may have a structure represented by and/or comprising Formula I, Formula II, Formula III, Formula IV, Formula IV′, Formula V, Formula V′, Formula VI, Formula VII, and/or Formula VIII as described herein. Compositions including compounds of the present invention along with methods of preparing and using the same are also described herein.

公开(公告)号：US20220080025A1

公开(公告)日：2022-03-17

申请号：US17420508

申请日：2020-01-06

Applicant: University of Vermont and State Agricultural College ,  Paredox Therapeutics, LLC ,  Wake Forest University Health Sciences

Inventor： Brian CUNNIFF ,  Gregory FRYKMAN ,  Kimberly Johnson NELSON

IPC: A61K38/12 ,  A61K31/355 ,  A61P35/00

Abstract: The invention relates, in part, to compounds, compositions, and methods useful to treat cancer in cells and subjects. The invention relates, in part, to compounds, compositions, and methods useful to treat cancer in cells and subjects. According to one aspect of the invention, methods for reducing cell viability in a population cells comprising cancer cells are provided, the methods including: contacting a population of cells that include cancer cells with Thiostrepton (TS) and Vitamin E-TPGS, under conditions and for a period of time sufficient for a statistically significant reduction in viability in a plurality of the cancer cells.

公开(公告)号：US11230702B2

公开(公告)日：2022-01-25

申请号：US16322232

申请日：2017-08-04

Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES

Inventor： Robert T. Wicks ,  Anthony Atala ,  Goodwell Nzou ,  Elizabeth E. Wicks

IPC: C12N5/071 ,  C12N5/00

Abstract: Provided herein is an in vitro model of the blood brain barrier. In some embodiments, the model includes: an endothelial cell layer, and brain tissue layer comprising neuronal cells, and optionally one or more of astrocytes, pericytes, oligodendrocytes, and microglia. In some embodiments, the model further comprises a porous membrane between said endothelial cell layer and the neuronal cell layer. A microfluidic device comprising the same and methods of use thereof are also provided.

公开(公告)号：US11136367B2

公开(公告)日：2021-10-05

申请号：US16704645

申请日：2019-12-05

Applicant: Wake Forest University Health Sciences

Inventor： Waldemar Debinski ,  Hetal Pandya ,  Denise Gibo

IPC: G01N33/532 ,  C07K14/54 ,  A61K47/64 ,  C07K14/34 ,  G01N33/50 ,  G01N33/68 ,  C07K14/21 ,  C07K19/00 ,  C07K14/005 ,  C07K14/195 ,  A61K38/00

Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.